Phil is the President and CEO of Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells in cancer, immunology and autoimmunity. He previously served as CEO of Faze Medicines, a biotechnology company focused on biomolecular condensates, and prior to joining Faze Medicines served as President and CEO of Northern Biologics, Inc., a company focused on the development of monoclonal antibodies as immuno-oncology therapeutics to treat targeted populations of cancer patients. Prior to joining Northern Biologics, from 2010 to 2017, he was global head of Research and Development at Shire, responsible for overseeing preclinical research and development, clinical research, regulatory affairs and medical affairs. Phil oversaw Shire’s growing product portfolio and as Executive Vice President and a member of Shire’s Executive Committee he played a key role in developing and executing Shire’s global business strategy, with a particular focus on rare diseases. Prior to joining Shire, he had roles of increasing responsibility in drug discovery in a range of therapeutic areas at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx.

Philip is currently a member of the board of directors of Revance Therapeutics. He holds a PhD in biochemistry from the University of Toronto and a BS in applied biochemistry from the University of Salford, Manchester UK. He was also a visiting fellow at the National Cancer Institute in Bethesda, Maryland.